 Jose Romero
Concepts (165)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Small Vessel Diseases | 6 | 2025 | 7 | 5.000 |
Why?
| | Dementia | 6 | 2025 | 168 | 3.200 |
Why?
| | Stroke | 12 | 2023 | 527 | 2.500 |
Why?
| | Magnetic Resonance Imaging | 14 | 2025 | 1507 | 2.300 |
Why?
| | Brain | 8 | 2025 | 1337 | 1.340 |
Why?
| | Cerebral Hemorrhage | 7 | 2023 | 102 | 1.020 |
Why?
| | Leukoencephalopathies | 1 | 2025 | 15 | 0.940 |
Why?
| | Diffusion Tensor Imaging | 1 | 2025 | 102 | 0.900 |
Why?
| | Cerebral Amyloid Angiopathy | 4 | 2023 | 4 | 0.670 |
Why?
| | Risk Factors | 13 | 2025 | 3971 | 0.580 |
Why?
| | Alzheimer Disease | 1 | 2022 | 356 | 0.580 |
Why?
| | Aged | 17 | 2025 | 10242 | 0.580 |
Why?
| | Humans | 38 | 2025 | 52441 | 0.520 |
Why?
| | Hypertension | 2 | 2020 | 560 | 0.480 |
Why?
| | Longitudinal Studies | 7 | 2025 | 756 | 0.480 |
Why?
| | Thrombolytic Therapy | 3 | 2020 | 113 | 0.470 |
Why?
| | Male | 22 | 2025 | 26874 | 0.460 |
Why?
| | Female | 23 | 2025 | 28277 | 0.450 |
Why?
| | Incidence | 8 | 2025 | 1096 | 0.440 |
Why?
| | Middle Aged | 14 | 2025 | 13133 | 0.440 |
Why?
| | Cohort Studies | 8 | 2025 | 1576 | 0.400 |
Why?
| | Brain Ischemia | 3 | 2020 | 168 | 0.400 |
Why?
| | Ischemic Attack, Transient | 2 | 2025 | 60 | 0.390 |
Why?
| | Tick-Borne Diseases | 1 | 2012 | 4 | 0.380 |
Why?
| | Risk Assessment | 4 | 2025 | 1349 | 0.360 |
Why?
| | Parechovirus | 1 | 2011 | 4 | 0.340 |
Why?
| | Viral Vaccines | 1 | 2011 | 16 | 0.340 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 816 | 0.340 |
Why?
| | Picornaviridae Infections | 1 | 2011 | 22 | 0.340 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2010 | 35 | 0.330 |
Why?
| | Respiratory Sounds | 1 | 2010 | 50 | 0.330 |
Why?
| | Antibodies, Viral | 1 | 2011 | 113 | 0.330 |
Why?
| | RNA, Viral | 1 | 2011 | 123 | 0.330 |
Why?
| | Infant, Premature, Diseases | 1 | 2010 | 93 | 0.310 |
Why?
| | Respiratory Tract Infections | 1 | 2010 | 82 | 0.310 |
Why?
| | Aged, 80 and over | 8 | 2025 | 3449 | 0.300 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 175 | 0.260 |
Why?
| | Coronavirus Infections | 2 | 2020 | 188 | 0.260 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 184 | 0.240 |
Why?
| | Tissue Plasminogen Activator | 3 | 2021 | 108 | 0.240 |
Why?
| | Sensitivity and Specificity | 2 | 2025 | 871 | 0.230 |
Why?
| | Motor Cortex | 2 | 2002 | 15 | 0.230 |
Why?
| | Reproducibility of Results | 2 | 2025 | 1223 | 0.210 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2023 | 4 | 0.210 |
Why?
| | Intra-Articular Fractures | 1 | 2023 | 4 | 0.210 |
Why?
| | Basal Ganglia | 1 | 2023 | 26 | 0.200 |
Why?
| | Infarction | 1 | 2022 | 14 | 0.200 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 131 | 0.190 |
Why?
| | Electromagnetic Fields | 1 | 2002 | 15 | 0.180 |
Why?
| | Mental Health | 1 | 2024 | 237 | 0.180 |
Why?
| | Early Medical Intervention | 1 | 2020 | 14 | 0.170 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 38 | 0.160 |
Why?
| | Neurology | 1 | 2020 | 39 | 0.160 |
Why?
| | Data Interpretation, Statistical | 1 | 2020 | 166 | 0.160 |
Why?
| | Radiography, Interventional | 1 | 2020 | 58 | 0.160 |
Why?
| | Societies, Medical | 1 | 2020 | 200 | 0.160 |
Why?
| | tau Proteins | 1 | 2019 | 31 | 0.150 |
Why?
| | Needs Assessment | 1 | 2020 | 141 | 0.150 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 177 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 148 | 0.150 |
Why?
| | Angiogenesis Inhibitors | 1 | 2010 | 183 | 0.150 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 161 | 0.150 |
Why?
| | Papillomavirus Vaccines | 1 | 2019 | 69 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2023 | 6694 | 0.140 |
Why?
| | Pharmacies | 1 | 2019 | 61 | 0.140 |
Why?
| | Community Pharmacy Services | 1 | 2019 | 71 | 0.140 |
Why?
| | Streptococcus pneumoniae | 1 | 2017 | 27 | 0.140 |
Why?
| | Pneumococcal Vaccines | 1 | 2017 | 16 | 0.140 |
Why?
| | Pneumococcal Infections | 1 | 2017 | 15 | 0.140 |
Why?
| | Endovascular Procedures | 1 | 2020 | 180 | 0.140 |
Why?
| | Adult | 6 | 2025 | 14205 | 0.130 |
Why?
| | Arthritis, Infectious | 1 | 2017 | 43 | 0.130 |
Why?
| | Stroke, Lacunar | 1 | 2016 | 1 | 0.130 |
Why?
| | Papillomavirus Infections | 1 | 2019 | 170 | 0.130 |
Why?
| | Prevalence | 1 | 2020 | 1016 | 0.130 |
Why?
| | Massachusetts | 3 | 2025 | 32 | 0.130 |
Why?
| | Emotions | 1 | 2017 | 172 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 475 | 0.120 |
Why?
| | Osteomyelitis | 1 | 2017 | 125 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 455 | 0.120 |
Why?
| | United States | 5 | 2020 | 5215 | 0.110 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2014 | 7 | 0.110 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2014 | 45 | 0.110 |
Why?
| | Leptin | 1 | 2015 | 148 | 0.110 |
Why?
| | Meningitis, Meningococcal | 1 | 2013 | 3 | 0.100 |
Why?
| | Meningococcal Infections | 1 | 2013 | 3 | 0.100 |
Why?
| | Child, Preschool | 4 | 2020 | 4046 | 0.100 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 2002 | 5 | 0.100 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2002 | 29 | 0.100 |
Why?
| | Bacteremia | 1 | 2013 | 87 | 0.100 |
Why?
| | Neutrophils | 1 | 2013 | 148 | 0.090 |
Why?
| | Infant | 4 | 2017 | 3709 | 0.090 |
Why?
| | Evoked Potentials, Motor | 2 | 2002 | 9 | 0.090 |
Why?
| | DNA, Complementary | 1 | 2002 | 129 | 0.090 |
Why?
| | Tularemia | 1 | 2012 | 19 | 0.090 |
Why?
| | Amyloid beta-Peptides | 2 | 2023 | 73 | 0.090 |
Why?
| | Ehrlichiosis | 1 | 2012 | 14 | 0.090 |
Why?
| | Lyme Disease | 1 | 2012 | 30 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1216 | 0.090 |
Why?
| | Pandemics | 3 | 2020 | 580 | 0.090 |
Why?
| | Upper Extremity Deep Vein Thrombosis | 1 | 2011 | 4 | 0.090 |
Why?
| | Embolism, Paradoxical | 1 | 2011 | 4 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 2002 | 245 | 0.090 |
Why?
| | Intracranial Embolism | 1 | 2011 | 29 | 0.090 |
Why?
| | Foramen Ovale, Patent | 1 | 2011 | 31 | 0.080 |
Why?
| | Administration, Intravenous | 2 | 2020 | 73 | 0.080 |
Why?
| | Child | 5 | 2023 | 7194 | 0.080 |
Why?
| | Prospective Studies | 3 | 2020 | 2433 | 0.070 |
Why?
| | Adolescent | 4 | 2023 | 6713 | 0.070 |
Why?
| | Infant, Premature | 1 | 2010 | 327 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2014 | 2871 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2010 | 1045 | 0.070 |
Why?
| | Time Factors | 2 | 2025 | 2987 | 0.060 |
Why?
| | Arkansas | 1 | 2012 | 2013 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2020 | 1202 | 0.060 |
Why?
| | Electromyography | 2 | 2002 | 128 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 4346 | 0.050 |
Why?
| | Methyltransferases | 1 | 2023 | 26 | 0.050 |
Why?
| | Joints | 1 | 2023 | 19 | 0.050 |
Why?
| | Radiography | 1 | 2023 | 469 | 0.050 |
Why?
| | Nerve Net | 1 | 2002 | 76 | 0.040 |
Why?
| | Brain Infarction | 1 | 2020 | 12 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2023 | 506 | 0.040 |
Why?
| | Atrophy | 1 | 2020 | 46 | 0.040 |
Why?
| | Polysomnography | 1 | 2020 | 76 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 525 | 0.040 |
Why?
| | Boston | 1 | 2020 | 13 | 0.040 |
Why?
| | Endocrine System Diseases | 1 | 2010 | 9 | 0.040 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 24 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 36 | 0.040 |
Why?
| | Vascular Diseases | 1 | 2020 | 75 | 0.040 |
Why?
| | Triage | 1 | 2020 | 66 | 0.040 |
Why?
| | Thrombectomy | 1 | 2020 | 74 | 0.040 |
Why?
| | Brain Mapping | 1 | 2020 | 221 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2020 | 5508 | 0.040 |
Why?
| | Skin Diseases | 1 | 2010 | 118 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2010 | 126 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 230 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 1140 | 0.040 |
Why?
| | Anticoagulants | 1 | 2021 | 276 | 0.030 |
Why?
| | Pharmacists | 1 | 2019 | 150 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2017 | 75 | 0.030 |
Why?
| | Vaccination | 1 | 2019 | 294 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 725 | 0.030 |
Why?
| | Microbial Sensitivity Tests | 1 | 2017 | 271 | 0.030 |
Why?
| | Waist-Hip Ratio | 1 | 2015 | 9 | 0.030 |
Why?
| | Radioimmunoassay | 1 | 2015 | 43 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 1677 | 0.030 |
Why?
| | Clavulanic Acids | 1 | 2014 | 8 | 0.030 |
Why?
| | Ticarcillin | 1 | 2014 | 8 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 493 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 446 | 0.030 |
Why?
| | Neisseria meningitidis | 1 | 2013 | 4 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2013 | 71 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2014 | 235 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 938 | 0.020 |
Why?
| | DNA Primers | 1 | 2002 | 204 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2002 | 412 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2002 | 375 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2002 | 176 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2002 | 1134 | 0.020 |
Why?
| | Prognosis | 1 | 2013 | 2100 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2002 | 115 | 0.010 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2002 | 72 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2002 | 197 | 0.010 |
Why?
|
|
Romero's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|